Utiva Cranberry PACs Review (2026): Does the Dose Match?

HerWellReport is reader-supported. This article contains affiliate links — see our affiliate disclosure. Nothing here is medical advice; see our medical disclaimer.

Search “Utiva Cranberry PACs review” and you get Utiva. Its own product page, its own FAQ, its own blog explaining PAC measurement, a Walmart listing, a Fullscript catalogue entry — nobody independent has actually sat down with the label and the research and checked whether the dose matches the evidence. So we did.

The short version: this is one of the few cranberry supplements on the market whose label dose actually lines up with what a real meta-analysis says works. That is a genuinely uncommon thing to be able to say. It does not make the product a cure, and one marketing claim on Utiva’s own site outruns its evidence — both things are true at once, and we will not soften either one.

Short on time? Skip to what we’d look at instead →

What’s actually in the capsule

Each Utiva Cranberry PACs capsule contains 36 mg of proanthocyanidins (PACs), sourced from 240 mg of cranberry juice extract under Utiva’s own branded name, ProPAC36. The company states the PAC content is measured by the DMAC/A2 method, which is the more rigorous of the two common lab methods for quantifying PACs (the other, BL-DMAC, tends to run less consistent between labs). The only other listed ingredients are hypromellose (the vegetable capsule shell) and brown rice flour (a filler). The product is vegan, halal and gluten-free, and Utiva says it is third-party tested with the vitamin K stripped out — a reasonable thing to flag for anyone on warfarin, though see the interaction note below.

Dosing is split by purpose: one capsule a day for ongoing maintenance, or two capsules followed by two more 24 hours later around a specific trigger (Utiva markets this second protocol for “sex-associated” symptoms). Neither protocol is a treatment for an active infection — more on that below.

The evidence, and why the dose matters more than the brand

Most cranberry supplements do not tell you how many milligrams of PACs are actually in a serving. That is the single biggest problem with the category, and it’s why a 2024 systematic review and meta-analysis in Frontiers in Nutrition exists at all¹: researchers pooled 10 randomised controlled trials covering 2,438 participants and asked, specifically, whether the PAC dose changes the outcome.

It does. At 36 mg of PACs or more per day, cranberry products were associated with an 18% reduction in UTI risk (risk ratio 0.82, 95% CI 0.69–0.98, p=0.03). Below 36 mg a day, the pooled effect was not statistically significant (p=0.39). The benefit also only showed up in trials where people used the product continuously for 12 to 24 weeks, and in all-female study populations — not a quick fix, and not (on this evidence) something that clearly works the same way in men.

Utiva’s 36 mg-per-capsule dose sits exactly at that threshold. That’s a real, checkable fact, and it’s rare: most cranberry pills on a pharmacy shelf either don’t publish a PAC number or publish one below 36 mg.

What that meta-analysis does not prove

It is evidence about cranberry PACs as a class, pooled across ten different products and extraction methods — not a clinical trial of Utiva Cranberry PACs specifically. We could not find a published, finished-product trial of this exact ProPAC36 extract. That is a normal gap in the supplement world (very few brands fund trials on their own finished product), but it means “meets the dose the research says matters” and “has been clinically tested” are two different claims, and only the first one is actually true here.

The claim we would not have signed off on

Utiva’s own marketing states that “96% of patients taking Utiva Cranberry PACs for 6+ months reduced their risk of recurrent UTIs,” based on a survey of more than 500 participants. That is self-reported outcome data from people who were already buying and using the product — not a controlled trial, and not directly comparable to the meta-analysis figures above. A survey like that can’t rule out placebo effect, recall bias, or the simple fact that people who stick with a supplement for six months tend to be a self-selected group who were already doing reasonably well. We’re noting it here because a reader comparing “96%” against the meta-analysis’s 18% risk reduction could easily walk away with the wrong impression of how strong the evidence actually is.

Price

Direct from the brand’s own site: a 30-day supply (30 capsules) runs $39.99 one-time, or $29.99 with a 25% subscribe-and-save discount. A 60-day supply is $74.98, and 90 days is $109.99 — modest per-unit savings, no dramatic bulk discount. That works out to roughly $1.22–$1.33 a day depending on pack size and whether you subscribe. Utiva offers a 30-day money-back guarantee on first-time orders placed directly through its own site; it does not cover subscription renewals or purchases made through a third-party retailer.

Who this actually fits

Cranberry PACs, at an evidence-matching dose, have data behind them for one specific thing: reducing the risk of recurrent UTIs in women, used continuously, over months. They are not a treatment for a UTI you already have, and NCCIH is explicit on that point² — see a clinician for an active infection. They also are not aimed at overactive bladder, urgency or leaks, which is a different mechanism and a different product category on this site (that’s what our FemiCore review covers). If what you’re actually dealing with is urgency and leaking rather than repeat infections, cranberry PACs are the wrong tool regardless of dose.

One more honest caveat: NCCIH describes cranberry’s interaction with the blood thinner warfarin as “conflicting” evidence, not settled either way² — worth a conversation with a pharmacist or prescriber before starting, rather than assuming the vitamin-K-free formulation resolves it.

Bottom line

Of the cranberry brands we’ve checked so far, Utiva is the one whose published dose actually matches what a real meta-analysis says is needed for a measurable effect. That is worth something, and it’s genuinely uncommon in this aisle. What it is not is a clinically tested finished product, and the “96% of patients” figure on Utiva’s own site is customer-survey marketing, not trial data — the two should not be read as equivalent. If recurrent UTIs are your specific problem and you want a cranberry supplement, this is one of the few we can point to a real dose-matching rationale for. If it’s urgency and leaking you’re dealing with, this isn’t the right category of product at all — see our FemiCore review for that, or browse the sourced grades in our ingredient dataset to compare cranberry against everything else we’ve checked.

FAQ

Is 36 mg of PACs actually a meaningful amount?
Per the 2024 Frontiers in Nutrition meta-analysis, yes — it’s the threshold below which pooled trial data showed no statistically significant benefit, and at or above which it did (an 18% relative risk reduction). Most cranberry supplements don’t disclose enough information to know which side of that line they fall on.

Does Utiva Cranberry PACs treat an active UTI?
No. NCCIH is explicit that cranberry is not a treatment for an existing infection. This is a prevention product, studied over months of continuous use, not a substitute for seeing a clinician when you have symptoms.

Is the “96% of patients” claim a clinical trial result?
No — it’s based on a customer survey of 500+ existing users, not a controlled study. Treat it as marketing, not evidence, and rely on the meta-analysis figures instead when comparing products.

More from HerWellReport

• FemiCore Review: Does It Actually Help With Bladder Control?
• Does Cranberry Actually Help Urinary Health?
• Recurrent UTIs in Women: What Actually Helps
• The Ingredient Dataset: 65 Bladder and Menopause Ingredients, Sourced